Search results
Results from the WOW.Com Content Network
The liver is a common site for metastatic disease because of its rich, dual blood supply (the liver receives blood via the hepatic artery and portal vein). Metastatic tumors in the liver are 20 times more common than primary tumors. In 50% of all cases the primary tumor is of the gastrointestinal tract; other common sites include the breast ...
Currently, if the hepatic adenoma is >5 cm, increasing in size, symptomatic lesions, has molecular markers associated with HCC transformation, rising level of liver tumor markers such as alpha fetoprotein, the patient is a male, or has a glycogen storage disorder, the adenoma is recommended to be surgically removed. [7]
The most common malignant tumors in the liver represent metastases (spread) from tumors which originate elsewhere in the body. [5] Among cancers that originate from liver tissue, HCC is the most common primary liver cancer.
Liver tumor types by relative incidence in adults in the United States (liver cancers in dark red color). [14] The most frequent liver cancer, accounting for approximately 75% of all primary liver cancers, is hepatocellular carcinoma (HCC). [15] HCC is a cancer formed by liver cells, known as hepatocytes, that become malignant. In terms of ...
The usual markers for liver disease – aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase – are often normal or only slightly elevated. FLC often does not produce alpha fetoprotein (AFP), a widely used marker for conventional hepatocellular carcinoma.
For example, tumor markers like Ki-67 can be used to choose form of treatment or in prognostics but are not useful to give a diagnosis, while other tumor markers have the opposite functionality. Therefore it's important to follow the guidelines of the specific tumor marker. Tumor markers are mainly used in clinical medicine to support a ...
Two areas in particular that are receiving attention as surrogate markers include circulating tumor cells (CTCs) [45] [46] and circulating miRNAs. [47] [48] Both these markers are associated with the number of tumor cells present in the blood, and as such, are hoped to provide a surrogate for tumor progression and metastasis. However ...
The L3 isoform is specific to malignant tumors and its detected presence can serve to identify patients whom need increased monitoring for the development of HCC in high risk populations (i.e. chronic hepatitis B and C and/or liver cirrhosis). AFP-L3% is now being considered as a tumor marker for the North American demographic.